文献速递细菌感染、耐药与抗菌药物

(脂)糖肽类联合β-内酰胺类抗MRSA的敏感性研究

Combinations of (lipo)glycopeptides with β-lactams against MRSA: susceptibility insights.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

BACKGROUND: Increasing application of vancomycin due to the high prevalence of MRSA infections has led to the emergence of vancomycin intermediate-resistant Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA).…

要点

  • β-内酰胺类可降低(脂)糖肽类对MRSA及hVISA/VISA/DNS的MIC值,最高达160倍。
  • 脂糖肽类(达巴万星、奥利万星、特拉万星)活性优于万古霉素和替考拉宁,MIC差异可达8倍。
  • 多数联合方案具杀菌活性且优于任一单药,但需进一步临床研究验证。

核心结论

  • (脂)糖肽类与β-内酰胺类联合对MRSA、hVISA、VISA及DNS表型可降低(脂)糖肽类MIC值并增强杀菌活性。

主要发现

  • 加入β-内酰胺类后,(脂)糖肽类对所有菌株的MIC值降低最高达160倍。
  • 脂糖肽类(达巴万星、奥利万星、特拉万星)与万古霉素和替考拉宁相比MIC值差异显著,最高达8倍。
  • 多数联合方案具杀菌活性且优于任一单药。

关键数值与推荐

  • MIC测定采用CLSI推荐的微量肉汤稀释法,部分抗生素需修改检测条件以显示最佳活性。
  • 24小时时间杀菌试验中,(脂)糖肽类的协同活性受MIC板及其表面积影响。

临床怎么用

  • 对于MRSA及万古霉素中介或耐药表型,可考虑(脂)糖肽类联合β-内酰胺类以降低MIC并增强杀菌,但需临床研究进一步验证。

局限性

  • 协同活性受检测条件(MIC板表面积)影响。
  • 需进一步临床研究验证联合方案的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Increasing application of vancomycin due to the high prevalence of MRSA infections has led to the emergence of vancomycin intermediate-resistant Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA). Consequently, the need for alternative therapies that target MRSA has become evident. OBJECTIVES: To evaluate the synergy between (lipo)glycopeptides (LGP/GPs) (vancomycin, teicoplanin, telavancin, dalbavancin and oritavancin) and β-lactams (ceftaroline, cefepime, cefazolin and oxacillin) against MRSA, hVISA, VISA and daptomycin non-susceptible (DNS) phenotypes. METHODS: Twenty randomly selected clinical MRSA strains (i.e. 5 MRSA, 5 hVISA, 5 VISA and 5 DNS) were assessed versus LGP/GPs alone and LGP/GPs in combination with β-lactams for MICs. Although verification of antibiotic potency against bacterial strains is assessed by the microbroth dilution (MBD) MIC method recommended by the CLSI, some antibiotics need modified assay conditions in order to demonstrate their optimal activity. RESULTS: Addition of β-lactams reduced MIC values of LGP/GPs against all strains (up to 160-fold reduction). In general, LGPs (dalbavancin, oritavancin and telavancin) were more active (significant differences in MIC values, up to 8-fold) compared with vancomycin and teicoplanin. The majority of these combinations were bactericidal and superior to any single agent. CONCLUSIONS: This report has examined the susceptibility patterns of LGP/GPs and their combination with β-lactams. Of interest, the impact of susceptibility tests (in terms of MIC plates and their surface area) on the synergistic activity in 24 h time-kill experiments was apparent for LGPs. Further clinical research is required to investigate synergy with LGP/GPs and β-lactams against these Staphylococcus strains.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Kebriaei R, Rice SA, Singh NB, et al. Combinations of (lipo)glycopeptides with β-lactams against MRSA: susceptibility insights. J Antimicrob Chemother. 2020. PMID: 32591820. doi:10.1093/jac/dkaa237

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。